MedTrace Logo

Usage of Meropenem/Gentamicin Versus Ceftazidime/Avibactam in ARDS

NCT04402359 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2020-06-09

No results posted yet for this study

Summary

This was a prospective double blind study conducted on 200 polytrauma patients admitted to King Abdul-Aziz Specialized Hospital, Taif, KSA between July 2018 and December 2019 in surgical ICU. All patients were having severe chest trauma, contused lungs either with or without severe head trauma.

Conditions

  • Ventilator Associated Pneumonia

Interventions

DRUG

meropenem

meropenem one gram slowly IV infusion every 8 hours for 14 days

DRUG

ceftazidime 2 grams and avibactam 500

received ceftazidime 2 grams and avibactam 500 mg every 8 hours for 14 days in solution for injection(sodium chloride 9 mg/mL (0.9%), sodium chloride 4.5 mg/mL, dextrose 25 mg/mL, 0.45% sodium chloride, 2.5% dextrose and/or Lactated Ringer's solution).

DEVICE

ventilator

all patients selected to be ventilated for 14 days

Sponsors & Collaborators

  • King Abdul Aziz Specialist Hospital

    lead NETWORK

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-05
Primary Completion
2019-12-28
Completion
2019-12-30
FDA Drug
Yes

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04402359 on ClinicalTrials.gov